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Implication for health policy/practice/research/medical education:
In a non-randomized, clinical trial to compare eight-week versus twelve-week corticosteroid treatment regimens in children 
with idiopathic nephrotic syndrome, we found twelve-week steroid treatment could significantly decrease the relapse rate in 
comparison with eight-week treatment because no significant difference in steroid resistance, steroid dependence, and frequent 
relapse between the two treatment protocols was observed.
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Nephrotic syndrome (NS) is a clinical condition caused by 
glomerular injury. It is characterized by edema, massive 
proteinuria, hypoalbuminemia, and hyperlipidemia. NS 
may be secondary to infectious diseases and systemic 
illnesses such as collagen vascular disease, malignancies, 
and primary renal disease (1).
In the pediatric age group, primary nephrotic syndrome 
Introduction: Nephrotic syndrome (NS) is the commonest chronic glomerular disease in 
children. Idiopathic NS can perfectly be controlled using corticosteroids in most instances, 
but a significant relapse rate of NS is still a major problem. Several treatment protocols are 
suggested to decrease relapse rate of NS in children. 
Objectives: The current clinical trial aimed at comparing the relapse rate between two 8- and 
12-week steroid treatment regimens.
Patients and Methods: In the current non-randomized, clinical trial, a total of 68 children 
with primary NS were enrolled. Oral prednisolone was administered to 34 patients for eight 
weeks (2 mg/kg/d and 1.5 mg/kg/alternate-day/each for four weeks) and other 34 patients 
for 12 weeks (2 mg/kg/d and 1.5 mg/kg/alternate-day/each for six weeks). A one-year follow-
up was completed for all the patients to evaluate relapse rate, steroid resistance, and steroid 
dependence.
Results: The remission rates were 47.1% and 73.5%, respectively in children of the eight- and 
12-week treatment groups because the difference was significant (P=0.026). The frequent 
relapse rates in the eight- and 12-week treatment groups were respectively 26.5% and 11.8%. 
Steroid dependence rate was 17.6% and 8.8% in the eight- and 12-week treatment groups 
respectively. The steroid resistance rates were respectively 8.8% and 5.9% in the eight- and 
12-week treatment groups.
Conclusion: Twelve-week steroid treatment can significantly decrease the relapse rate in 
comparison with eight-week treatment because no significant difference in steroid resistance, 
steroid dependence, and frequent relapse between the two treatment protocols was observed.
Trial registration: This study was approved by Iranian Registry of Clinical Trials (identifier: 
IRCT201404269014N33; https://www.irct.ir/trial/9472),
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(PNS) constitutes about 80% of cases (1,2) with the 
annual incidence rate of 2-7 per 105 in children under 16 
years old with higher prevalence in males (3). The most 
common type of PNS in children is minimal changes 
disease (MCD) that encompasses 90% of cases with 
favorable response to corticosteroid therapy (4). Children 
aged 1-12 years, without hypertension, gross hematuria, 
hypocomplementemia, permanent loss of renal function, 
and extra-renal manifestations are considered to have 
MCD while treatment could be started for them without 
renal biopsy. NS in children may be associated with 
complications such as infection, thromboembolism, and 
need for hospital admission to control edema and renal 
biopsy, which can cause inconvenience for patients and 
their families and impose a significant financial burden on 
the health system (5). Therefore, appropriate management 
of NS would be of great importance in clinical practice for 
pediatrics and pediatric nephrologists. 
The first drug of choice to treat NS in children is 
steroids (6). About 90% of patients with MCD respond 
to steroids, while approximately 10% are resistant (7,8). 
Approximately, a three-week steroid therapy is effective 
in 80%-90% of children, but most of the patients with NS 
have at least one recurrence. 
The length of treatment with steroids has remained a 
matter of debate in children with NS. There is almost no 
standard treatment guideline all over the world due to lack 
of strong supporting evidence (9). To minimize the risk of 
relapse and cumulative steroid dose, different treatment 
protocols are employed. International study of kidney 
disease in children (ISKD) suggested a four-week regimen 
of prednisone 60 mg/m2/day followed by another four-week 
regimen of 40 mg/m2 for three consecutive days per week 
(10). Another study suggested that daily administration 
of prednisone after the initial four weeks, if alternate-day 
prednisone given as a single dose, could decrease relapse 
rate in patients (11). Ehrisch et al concluded that six weeks 
daily treatment with 60 mg/m2 prednisone and six weeks 
alternate-day treatment with 40 mg/m2 prednisone would 
decrease relapse rate in comparison with four weeks daily 
and four weeks alternate-day treatment (12). Another 
study recommended a six-week regimen of 2 mg/kg 
prednisone daily followed by a further six-week regimen 
of 1.5 mg/kg alternate-day to treat children with NS (13).
The long-term side effects such as hypertension, 
hyperglycemia, osteoporosis, and growth failure 
should be considered when deciding on the duration of 
corticosteroid therapy (7). 
Objectives
In this study, we tried to compare effect of two steroid 
treatment protocols (eight weeks versus twelve weeks) 
regarding the rate of relapse, steroid dependence and 
steroid resistance in children with NS.
Patients and Methods
Study design 
A total of 68 children diagnosed with PNS referred 
to the pediatric nephrologist clinic enrolled in the 
study. Children with secondary NS, malnutrition, liver 
diseases, pancreatic insufficiency, celiac disease, Crohn’s 
disease, and the individuals who previously treated with 
phenobarbital, rifampin, phenytoin, and isoniazid were 
excluded.
Patients in the present study were assigned to two 
groups: the first group underwent an eight-week 
prednisolone therapy and the second group was treated 
for 12 weeks with prednisolone, then at the end of the 
treatment, relapse, steroid dependence, steroid resistance, 
and frequent relapse were evaluated and compared 
between the two groups.
Assignment of the subjects to groups was performed 
based on the date of attendance at the clinic. In the 
beginning, the study objectives were explained to 
children’s parents and written informed consent was 
taken. The first group was treated with prednisolone for a 
total duration of eight weeks (four weeks; 2 mg/kg/d and 
then four weeks; 1.5 mg/kg/alternate-day) and the second 
group was treated with the same medication for a total 
duration of 12 weeks (six weeks; 2 mg/kg/d and then six 
weeks; 1.5 mg/kg/alternate-day).
All the patients were monitored by testing their urine 
with dipsticks three times a week at home by parents and 
at least monthly by urine analysis to detect proteinuria. 
Patients were followed up for at least one year since 
resistance to prednisolone, frequent relapse, remission, 
and steroid dependence were documented in their records 
(Figure 1). 
Definitions
Steroid resistance: Significant proteinuria continued 
despite a four-week administration of 2 mg/kg/d 
prednisolone.
Steroid dependence: Relapse of proteinuria after reduction 
of dose or within two weeks after discontinuation of 
steroid therapy.
Frequent relapse: Two or more relapses in six months or 
four relapses in a year.
Relapse: Recurrence of proteinuria (dipstick testing ≥ 2+) 
for three consecutive days.
Remission: Negative to trace urine protein for three 
consecutive days.
Ethical issues
This research was conducted following the Declaration 
of Helsinki principles. Informed written consent was 
obtained from the patients or their parents. This study 
was approved by the Ethics Committee of Human 
Research at Hamadan University of Medical Sciences 
(#D/P/16/35/9/2932) and registered in Iranian Registry 
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of Clinical Trials (identifier: IRCT201404269014N33; 
https://www.irct.ir/trial/9472). Additionally, this study 
was extracted from the thesis of Aminosadat Sharif in 
Hamadan University of Medical Sciences.
Data analysis
Data were extracted from patients’ records and transferred 
into forms. Then, the results of the two groups were 
statistically analyzed by SPSS software. Chi-square 
test was used for comparing gender, steroid resistance, 
steroid dependence, frequent relapses, remission rates 
and independent t test for age distribution difference 
between two groups, while P value < 0.05 was considered 
as statistically meaningful.
Results
In this study, 68 children with PNS were recruited. In the 
eight-week treatment group, 22 of 34 patients (64.7%) 
were male and 12 (35.3%) female. On the other hand, in 
the 12-week treatment group, 24 patients (70.6%) were 
male and 10 (29.4%) female, since the gender difference 
was not significant (P = 0.24; Table 1).
The mean age of children in the eight- and 12-week 
treatment groups were 4 ± 1.67 and 4.9± 1.97 years 
respectively, while no significant difference between the 
groups regarding age distribution was observed (P = 0.83; 
Table 2).
In the current study, 16 (47.1%) and 25 (73.5%) of 
the patients in the eight- and 12-week groups were in 
remission until the end of study, which showed a significant 
difference between the groups (P = 0.026; Table 3).
In the eight-week treatment group, six patients (17.6%) 
and in the twelve-week group three (8.8%) had frequent 
relapses. Difference was not statistically significant 
(P = 0.283; Table 4).
In the eight-week treatment group, nine patients 




Assessed for eligibility (n=68) 
Excluded  (n=0) 
   Not meeting inclusion criteria (n=0) 
   Declined to participate (n=0) 
   Other reasons (n=0) 
Analysed  (n=34) 
 Excluded from analysis (n=0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to 8-week steroid treatment (n=34) 
 Received 8-week steroid treatment (n=34) 
 Did not receive 8-week steroid treatment 
(n=0) 
 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
 
Allocated to 12-week steroid treatment (n=34) 
 Received 12-week steroid treatment (n=34) 
 Did not receive 12-week steroid treatment 
(n=0) 
Analysed  (n=34) 







Figure 1. COSORT flow diagram of the study.




8-wk, No. (%) 12-wk, No. (%)
Male 22 (64.7) 24 (70.6)
0.24Female 12 (35.3) 10 (29.4)
All 34 (100) 34 (100)
Table 2. Age distribution in two groups
Group No. Mean age ± SD (y) P valuea
8-wk treatment 34 4 ± 1.67
0.83
12-wk treatment 34 4.09 ± 1.97
a Independent samples t test.









treatment 25 (73.5) 9 (26.5)
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(11.8%) became steroid dependent, however difference 
was not statistically significant (P = 0.123; Table 5).
In the eight-week treatment group, three patients 
(26.5%) and in the twelve-week group two patients (11.8%) 
were steroid resistant. Difference was not statistically 
significant (P = 0.642; Table 6). 
 
Discussion
One of the major therapeutic challenges in children with 
NS is the duration of corticosteroid therapy. Different 
treatment protocols are suggested to both reduce the risk 
of relapse and decrease steroid side effects, but there are 
controversies about optimum dose and duration of the 
treatment yet.
Webb et al conducted a study on 283 children presenting 
with the first episode of SSNS (steroid-sensitive nephrotic 
syndrome). The control group received prednisolone 60 
mg/m2/day in weeks 1-4, 40 mg/m2/on alternate days in 
weeks 5-8 and placebo on alternate days in weeks 9-18 
(total 2240 mg/m2). The intervention group received 
extended course prednisolone treatment: 60 mg/m2/day in 
weeks 1-4, then 60 mg/m2 on alternate days in weeks 5-18 
tapering by 10 mg/m2 every 2 weeks (total 3150 mg/m2). 
Extended course (EC) prednisolone was administered 
to the intervention groups in weeks 1-4 followed by 
descending doses on alternate days in weeks 5-16, as well 
as every two weeks (total 3150 mg/m2). The time to first 
relapse, frequent relapse, steroid dependency, and need 
for other immunosuppressive therapies had no significant 
difference between the groups. They finally concluded 
that EC prednisolone therapy had no clinical benefits; 
however, the EC therapy was more cost-effective than the 
SC therapy (14).
Difference between the current study and that of Webb 
et al, was the number of patients (68 versus 283), duration 
of treatment (six and eight weeks versus eight and 16 
weeks), employment of the placebo in their study, dosage 
of prednisolone, duration of follow-up (at least one year 
versus two years), and the final results. 
Paul et al evaluated the difference between the eight-
week standard corticosteroid regimen and the 12-week 
regimen in the treatment of NS. They divided 93 children 
with idiopathic NS into two groups; standard treatment 
(n=46) and long-term treatment (n=47). Patients in the 
standard group were treated with a four-week regimen 
of prednisolone followed by another four-week regimen 
with a lower dose on alternate days. The long-term 
group patients were treated with a six-week regimen of 
prednisolone followed by a lower dose on alternate days. 
Relapse in the next year was the primary outcome. In the 
current study, no significant difference was seen between 
the two groups in terms of relapse within the next year. 
Paul et al finally concluded that long-term prednisolone 
therapy does not influence the initial episode of steroid-
sensitive idiopathic nephrotic syndrome (15).
The difference between the current study and the study 
by Paul et al, was the number of patients (68 versus 93), 
the studied outcomes (prednisolone resistance, frequent 
relapse, relapse rate, remission, steroid dependence, 
and relapse within one year), and results (since 12-
week steroid treatment can significantly decrease the 
relapse rate compared to eight-week treatment, while 
long-term prednisolone therapy was not effective in the 
initial episode of steroid-sensitive idiopathic nephrotic 
syndrome). The dosage and type of medication, duration 
of follow-up, and number of samples in each group were 
the same in the two studies. 
Sinha et al, in a study on 182 children with NS, 
investigated the differences in treatment outcomes 
between the three- and six-month corticosteroid regimens. 
Children were divided into two groups; after 12 weeks 
of standard therapy for both groups, one group received 
tapering prednisolone for another 12 weeks, while the 
other group received placebo for a further 12 weeks. The 
study results show that long-term prednisolone therapy 
in the initial phase did not affect the disease course in 
children with steroid-sensitive NS (16). 
In a study by Mishra et al, 80 children were randomly 
treated with a five-month or a three-month prednisolone. 
After a one-year follow-up to record the frequency of 
relapses and side effects of steroid, the results showed 
a remarkable efficacy for the long-term prednisolone 
therapy in the initial episode of nephrotic syndrome, 
since the rate of relapse reduced, but the risk of steroid 
side effects did not increase (17).
Difference between our study and that of Mishra et 
al was the number of patients (68 versus 80), duration 
of treatment (12 and eight weeks versus three and five 





8-wk treatment 6 (17.6) 28 (82.4) χ2 = 1.15
df = 1
P value= 0.28312-wk treatment 3 (8.8) 31 (91.2)
Table 5. Steroid dependence in the two groups
Group
Steroid dependence, No. (%)
Chi-square test
Yes No
8-wk treatment 9 (26.5) 25 (73.5) χ2 = 2.37
df = 1
P value= 0.12312-wk treatment 4 (11.8) 30 (88.2)
Table 6. Steroid resistance in two groups
Group
Steroid resistance, No. (%)
Chi-square test
Yes No
8-wk treatment 3 (26.5) 31 (73.5) χ2 = 0.216
df = 1
P value= 0.64212-wk treatment 2 (11.8) 32 (88.2)
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months), and outcomes, which were studied during 
follow-up; however, the final result was the same in the 
two studies. 
Additionally, Beak et al reviewed the medical records of 
99 patients; 54 patients received short-term treatment (an 
eight-week prednisolone therapy including a four-week 
daily administration plus a further four-week with a lower 
dose on every alternate day basis), while 45 patients received 
long-term steroid treatment (a 12-week prednisolone 
therapy including six weeks of daily administration plus 
a further six-week with a lower dose on every alternate 
day basis). They found that relapse rate was significantly 
lower one year after the first nephrotic syndrome episode 
in children receiving long-term treatment compared with 
the patients receiving short-term treatment (8). The type 
of medication, duration, dose of the drugs, results of 
the remission, and relapse frequency in the groups were 
the same in Beak et al and our study, while differences 
were the number of patients (99 versus 68 in our study), 
duration of follow-up (at least two years versus at least one 
year in our study). In addition, Beak et al had not assessed 
prednisolone resistance and dependency in their study. 
Conclusion
According to the current study results, a higher remission 
rate and lower relapse rate was observed in children 
receiving a 12-week steroid therapy for the first episode of 
idiopathic nephrotic syndrome compared to the patients 
treated with an eight-week regimen of steroid, but no 
significant difference was observed between the treatment 
groups regarding steroid dependence, steroid resistance, 
and frequent relapse. However, further studies with larger 
sample sizes and longer follow-ups, as well as cost-efficacy 
and steroid side effects evaluations are needed. 
Limitations of the study
Small sample size of two groups and short duration 
of follow up (one year) were limitations of our study. 
Larger studies with longer duration of follow up are 
recommended.
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